Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ARQT 
Arcutis Biotherapeutics Inc (ARQT)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: ARQT (5-star) is a STRONG-BUY. BUY since 66 days. Simulated Profits (28.49%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $23.38
1 Year Target Price $23.38
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 156.39% | Avg. Invested days 34 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.48B USD | Price to earnings Ratio - | 1Y Target Price 23.38 |
Price to earnings Ratio - | 1Y Target Price 23.38 | ||
Volume (30-day avg) 7 | Beta 2.06 | 52 Weeks Range 8.03 - 21.56 | Updated Date 10/14/2025 |
52 Weeks Range 8.03 - 21.56 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.73 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -35.4% | Operating Margin (TTM) -17.93% |
Management Effectiveness
Return on Assets (TTM) -13.46% | Return on Equity (TTM) -57.33% |
Valuation
Trailing PE - | Forward PE 263.16 | Enterprise Value 2467322907 | Price to Sales(TTM) 9.43 |
Enterprise Value 2467322907 | Price to Sales(TTM) 9.43 | ||
Enterprise Value to Revenue 9.36 | Enterprise Value to EBITDA -2.04 | Shares Outstanding 119905078 | Shares Floating 85655392 |
Shares Outstanding 119905078 | Shares Floating 85655392 | ||
Percent Insiders 1.86 | Percent Institutions 112.57 |
Upturn AI SWOT
Arcutis Biotherapeutics Inc
Company Overview
History and Background
Arcutis Biotherapeutics, Inc. was founded in 2016. It is a late-stage biopharmaceutical company focused on developing and commercializing novel, differentiated therapies for immune-mediated dermatological diseases. Their focus has been on innovation in topical treatments.
Core Business Areas
- Dermatology Therapeutics: Focuses on developing and commercializing therapies for inflammatory skin diseases, including plaque psoriasis, atopic dermatitis, seborrheic dermatitis and other skin conditions.
Leadership and Structure
The leadership team includes Todd Simpson (CEO), Scott Burrows (CFO), and other executives in research, development, and commercialization. The organizational structure is typical of a biopharmaceutical company with departments focused on R&D, clinical trials, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- ZORYVE (roflumilast) topical cream 0.3%: A phosphodiesterase-4 (PDE4) inhibitor approved for the treatment of plaque psoriasis in patients 12 years and older. They also have studies going for Atopic Dermatitis. Market share data is still developing as it's a relatively new product. Competitors include topical corticosteroids, vitamin D analogs, and other topical PDE4 inhibitors.
- VTAMA (tapinarof) cream, 1%: Approved for the treatment of adults with plaque psoriasis. They acquired this medication after the acquisition of Ducentis BioTherapeutics Limited. Market share data is still developing as it's a relatively new product. Competitors include topical corticosteroids, vitamin D analogs and biologics
Market Dynamics
Industry Overview
The dermatology therapeutics market is driven by a high prevalence of skin conditions and a growing demand for effective and safe treatments. The market is competitive, with established players and emerging biotech companies. It is expected to grow with an aging population and increased awareness of skin health.
Positioning
Arcutis positions itself as an innovative dermatology company focused on developing differentiated topical therapies with improved efficacy and safety profiles. They aim to address unmet needs in the treatment of common skin conditions.
Total Addressable Market (TAM)
The global dermatology market is estimated to be worth tens of billions of dollars. Arcutis is positioned to capture a portion of this market with its approved products and pipeline candidates, targeting specific patient populations within the larger market.
Upturn SWOT Analysis
Strengths
- Innovative topical therapies
- Strong clinical trial results for key products
- Experienced management team
- Focus on unmet needs in dermatology
Weaknesses
- Reliance on successful commercialization of key products
- Limited product portfolio
- Competition from established players with broader product offerings
- Potential challenges in securing reimbursement and market access
Opportunities
- Expansion of approved products into new indications
- Development of new therapies for other dermatological conditions
- Strategic partnerships and collaborations
- Geographic expansion into international markets
Threats
- Regulatory hurdles and delays
- Competition from new and existing therapies
- Patent expirations
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- VRX
- LLY
- MRK
- BMY
Competitive Landscape
Arcutis has an advantage over its competitors in that its innovative topicals offer increased efficacy and safety over their alternatives. However, their broad portfolios, larger market share, and greater resources pose a risk.
Major Acquisitions
Ducentis BioTherapeutics Limited
- Year: 2023
- Acquisition Price (USD millions): 230
- Strategic Rationale: Arcutis acquired Ducentis to secure global rights to VTAMA (tapinarof) cream, a novel, first-in-class, steroid-free topical therapy approved for the treatment of plaque psoriasis.
Growth Trajectory and Initiatives
Historical Growth: Arcutis has experienced significant revenue growth since the commercial launch of its first product.
Future Projections: Analysts project continued revenue growth driven by increased adoption of its products and potential expansion into new indications. The company is expected to achieve profitability in the coming years.
Recent Initiatives: Recent initiatives include expanding the commercial team, launching new marketing campaigns, and advancing its pipeline of clinical development programs.
Summary
Arcutis Biotherapeutics is an emerging player in the dermatology market with innovative topical therapies. It has had a growing revenue and has secured global rights to tapinarof. However, commercial success and competition from larger, well-established companies are key risks. Overall, Arcutis has potential for future growth within the dermatology market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Arcutis Biotherapeutics Investor Relations
- Company Filings (SEC)
- Analyst Reports
- Market Research Reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market share data may be estimated. Financial data is based on the most recent available information and may be subject to change. The AI-based rating is a subjective assessment and should be used as one factor in a comprehensive investment analysis.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Arcutis Biotherapeutics Inc
Exchange NASDAQ | Headquaters Westlake Village, CA, United States | ||
IPO Launch date 2020-01-31 | President, CEO & Director Mr. Todd Franklin Watanabe M.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 342 | Website https://www.arcutis.com |
Full time employees 342 | Website https://www.arcutis.com | ||
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.